Project Grant K99AI190118
- Federal Project Grant Award Summary Emory University's Office of Sponsored Programs received a $430,375 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective August 1, 2025, with completion scheduled for July 31, 2027. The award funds investigator-initiated biomedical research examining inter-membrane lipid signaling mechanisms in gram-negative bacteria, specifically focusing on...
- Federal Grant Award Summary Emory University received a $6.11 million Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded July 25, 2025, and extending through June 30, 2029. The project, titled "Form with Function: Rapid Phenotypic Carbapenemase Testing to Improve Detection of Carbapenemase-Producing Organisms," develops an innovative diagnostic solution to address...
- Federal Grant Award Summary Emory University received a $160,546 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective September 3, 2025, with a completion date of August 31, 2029. The grant supports a research initiative titled "Towards Foundation Epidemic Models for Respiratory Infections: A Novel Spatiotemporal Machine Learning Framework." The project will be...
- Federal Grant Award Summary Emory University received a $346,214 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded on June 27, 2025, with a completion date of January 31, 2028. The grant supports investigator-initiated biomedical research focused on identifying and characterizing the mechanisms underlying beneficial effects of influenza A virus (IAV) co-infection within host...
- Federal Grant Award Summary Emory University received a $160,448 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) on March 10, 2026, with completion targeted for September 10, 2028. The award supports research investigating antiviral resistance mechanisms to acyclic phosphonates in orthopoxviruses, specifically addressing the therapeutic potential of repurposed compounds tenofovir...
- Federal Grant Award Summary Emory University received a $711,555 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective May 13, 2025, through April 30, 2030. The project delivers an integrated research and development framework combining graph neural networks with traditional compartmental models to advance understanding of spatiotemporal transmission dynamics and control...
- Federal Grant Award Summary Emory University received a $412,749 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) beginning February 6, 2026 and concluding January 31, 2028. The award supports research to identify and characterize cis-regulatory elements (enhancers) that facilitate precise genetic manipulation of specific B-cell subsets. The research will advance understanding of the...
- Federal Project Grant Award Summary The National Institute of Allergy and Infectious Diseases (NIAID) awarded $415,250 to the University of Georgia Research Foundation under the Allergy and Infectious Diseases Research program (CFDA 93.855) on August 21, 2025, for a research project extending through July 31, 2027. This project addresses the critical public health challenge of antibiotic resistance in gram-negative bacteria by characterizing a feedback signaling mechanism that regulates the...
- Federal Project Grant Award Summary Emory University received a $146,922 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) effective May 15, 2025, with a completion date of February 6, 2028. The grant supports multidisciplinary research focused on understanding and overcoming drug resistance in the SARS-CoV-2 main protease (Mpro) to nirmatrelvir (the active ingredient in Paxlovid),...
- Federal Grant Award Summary Wayne State University received a $455,719 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 3, 2026, with a completion date of March 31, 2028. The research initiative, conducted in Detroit, Michigan, focuses on investigating the mechanisms underlying phage-antibiotic synergy and resistance in daptomycin-resistant Enterococcus faecium (E....
Emory University received a $161,244 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), effective April 16, 2026, with a completion date of March 31, 2028. The research project focuses on understanding multidrug-resistant pathogen infections and evaluating treatment approaches using both antibiotics and bacteriophages. The research will employ experimental evolution assays to elucidate evolutionary trajectories toward antibiotic resistance in Staphylococcus aureus, Pseudomonas aeruginosa, and Escherichia coli, utilizing Galleria mellonella larvae as an in vivo model system to investigate how immune responses alter resistance development patterns. The project will characterize the genetic basis of antibiotic resistance through adaptive laboratory evolution experiments conducted with clinically used antibiotics. Researchers will identify the genetic variants responsible for resistance, determine the order of appearance of these mutations, and evaluate their individual contributions to observed resistance phenotypes. Additionally, the study will assess fitness costs associated with resistance mutations and examine cross-resistance and collateral susceptibility patterns. These research products are intended to establish foundational knowledge for developing new treatment protocols to combat life-threatening bacterial infections caused by the ESKAPE group pathogens, which account for significant morbidity and mortality in healthcare settings.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $161.2k | 4/17/26 |